• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form FWP filed by AbbVie Inc.

    2/18/25 9:25:54 PM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ABBV alert in real time by email
    FWP 1 tm255723d5_fwp.htm FWP

    Filed pursuant to Rule 433
    Dated February 18, 2025
    Issuer Free Writing Prospectus supplementing the
    Preliminary Prospectus Supplement dated
    February 18, 2025 and the
    Prospectus dated February 14, 2025
    Registration No. 333-284980

     

    AbbVie Inc.

     

    Pricing Term Sheet

     

    $1,250,000,000 4.650% Senior Notes due 2028 (the “2028 Notes”)

    $1,000,000,000 4.875% Senior Notes due 2030 (the “2030 Notes”)

    $1,000,000,000 5.200% Senior Notes due 2035 (the “2035 Notes”)

    $750,000,000 5.600% Senior Notes due 2055 (the “2055 Notes”)

     

    Terms Applicable to Each Series of the Notes

     

    Issuer: AbbVie Inc.
       
    Trade Date: February 18, 2025
       
    Settlement Date*: February 26, 2025 (T+6)
       
    Ratings**: A3 (Positive) by Moody’s Investors Service, Inc. / A- (Stable) by Standard & Poor’s Ratings Group Inc.
       
    Form of Offering: SEC Registered (Registration No. 333-284980)
       
    Joint Book-Running Managers: BofA Securities, Inc. (All Notes)
      J.P. Morgan Securities LLC (All Notes)
      Morgan Stanley & Co. LLC (All Notes)
      Barclays Capital Inc. (All Notes)
      Mizuho Securities USA LLC (All Notes)
      BNP Paribas Securities Corp. (2028 Notes)
      Citigroup Global Markets Inc. (2055 Notes)
      Deutsche Bank Securities Inc. (2030 Notes)
      Goldman Sachs & Co. LLC (2055 Notes)
      HSBC Securities (USA) Inc. (2030 Notes)
      SG Americas Securities, LLC (2035 Notes)
      Wells Fargo Securities, LLC (2035 Notes)
       
    Co-Managers: BNP Paribas Securities Corp. (2030 Notes, 2035 Notes, 2055 Notes)
      Citigroup Global Markets Inc. (2028 Notes, 2030 Notes, 2035 Notes)
      Deutsche Bank Securities Inc. (2028 Notes, 2035 Notes, 2055 Notes)
      Goldman Sachs & Co. LLC (2028 Notes, 2030 Notes, 2035 Notes)
      HSBC Securities (USA) Inc. (2028 Notes, 2035 Notes, 2055 Notes)
      SG Americas Securities, LLC (2028 Notes, 2030 Notes, 2055 Notes)
      Wells Fargo Securities, LLC (2028 Notes, 2030 Notes, 2055 Notes)
      Lloyds Securities Inc. (All Notes)
      MUFG Securities Americas Inc. (All Notes)
      Santander US Capital Markets LLC (All Notes)
      TD Securities (USA) LLC (All Notes)
      U.S. Bancorp Investments, Inc. (All Notes)
      Siebert Williams Shank & Co., LLC (All Notes)
      Bancroft Capital, LLC (All Notes)
      Cabrera Capital Markets LLC (All Notes)
      Independence Point Securities LLC (All Notes)
      R. Seelaus & Co., LLC (All Notes)
       
    Interest Payment Dates: March 15 and September 15, commencing September 15, 2025
       
    Day Count Convention: 30 / 360

     

     

     

     

     

     

    Terms Applicable to 4.650% Senior Notes due 2028

     

    Aggregate Principal Amount: $1,250,000,000
    Final Maturity Date: March 15, 2028
    Public Offering Price: 99.867%, plus accrued and unpaid interest, if any, from February 26, 2025
    Benchmark Treasury: 4.250% due February 15, 2028
    Benchmark Treasury Price and Yield: 99-25 ¼ / 4.326%
    Spread to Benchmark Treasury: T+37 bps
    Coupon: 4.650%
    Yield to Maturity: 4.696%
    Make-Whole Call: Make-whole call at T+10 bps
    Par Call: On or after February 15, 2028
    CUSIP / ISIN: 00287Y DY2 / US00287YDY23

     

     

     

    Terms Applicable to 4.875% Senior Notes due 2030

     

    Aggregate Principal Amount: $1,000,000,000
    Final Maturity Date: March 15, 2030
    Public Offering Price: 99.908%, plus accrued and unpaid interest, if any, from February 26, 2025
    Benchmark Treasury: 4.250% due January 31, 2030
    Benchmark Treasury Price and Yield: 99-11+ / 4.395%
    Spread to Benchmark Treasury: T+50 bps
    Coupon: 4.875%
    Yield to Maturity: 4.895%
    Make-Whole Call: Make-whole call at T+10 bps
    Par Call: On or after February 15, 2030
    CUSIP / ISIN: 00287Y DZ9 / US00287YDZ97

     

     

     

    Terms Applicable to 5.200% Senior Notes due 2035

     

    Aggregate Principal Amount: $1,000,000,000
    Final Maturity Date: March 15, 2035
    Public Offering Price: 99.857%, plus accrued and unpaid interest, if any, from February 26, 2025
    Benchmark Treasury: 4.625% due February 15, 2035
    Benchmark Treasury Price and Yield: 100-19+ / 4.548%
    Spread to Benchmark Treasury: T+67 bps
    Coupon: 5.200%
    Yield to Maturity: 5.218%
    Make-Whole Call: Make-whole call at T+15 bps
    Par Call: On or after December 15, 2034
    CUSIP / ISIN: 00287Y EA3 / US00287YEA38

     

     

     

    Terms Applicable to 5.600% Senior Notes due 2055

     

    Aggregate Principal Amount: $750,000,000
    Final Maturity Date: March 15, 2055
    Public Offering Price: 99.750%, plus accrued and unpaid interest, if any, from February 26, 2025
    Benchmark Treasury: 4.500% due November 15, 2054
    Benchmark Treasury Price and Yield: 95-15 / 4.787%
    Spread to Benchmark Treasury: T+83 bps
    Coupon: 5.600%
    Yield to Maturity: 5.617%
    Make-Whole Call: Make-whole call at T+15 bps
    Par Call: On or after September 15, 2054
    CUSIP / ISIN: 00287Y EB1 / US00287YEB11

     

     

     

     2 

     

     

    The Issuer has filed a registration statement (including a preliminary prospectus supplement and an accompanying prospectus) with the Securities and Exchange Commission (“SEC”) for the offering to which this communication relates.  Before you invest, you should read the prospectus in that registration statement and other documents that the Issuer has filed with the SEC, including the preliminary prospectus supplement, for more complete information about the Issuer and this offering.  You may get these documents for free by visiting the SEC website at www.sec.gov.  Alternatively, the Issuer, any underwriter or any dealer participating in the offering will arrange to send you the preliminary prospectus supplement and the accompanying prospectus if you request it by contacting BofA Securities, Inc. at 1-800-294-1322, J.P. Morgan Securities LLC collect at 1-212-834-4533, Morgan Stanley & Co. LLC at 1-866-718-1649, Barclays Capital Inc. at 1-888-603-5847 and Mizuho Securities USA LLC at 1-866-271-7403.

     

    *The Issuer expects to deliver the Notes against payment for the Notes on or about February 26, 2025, which will be the sixth business day following the date of the pricing of the Notes (this settlement cycle being referred to as “T+6”). Under Rule 15c6-1 of the Exchange Act, trades in the secondary market generally are required to settle in one business day, unless the parties to a trade expressly agree otherwise. Accordingly, purchasers who wish to trade Notes on the date of pricing will be required, by virtue of the fact that the Notes initially will settle in T+6, to specify alternative settlement arrangements to prevent a failed settlement.

     

    **These Issuer ratings are not a recommendation to buy, sell or hold the Notes offered hereby. The ratings may be subject to revision or withdrawal at any time by the relevant rating agency. Each of the Issuer ratings included herein should be evaluated independently of any other Issuer rating.

     

    Terms used but not defined herein shall have the meanings ascribed thereto in the Issuer’s preliminary prospectus supplement, dated February 18, 2025, to the Issuer’s prospectus, dated February 14, 2025.

     

     3 

     

    Get the next $ABBV alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ABBV

    DatePrice TargetRatingAnalyst
    1/8/2026Outperform → Peer Perform
    Wolfe Research
    1/7/2026$240.00Neutral
    UBS
    12/10/2025$265.00Hold → Buy
    HSBC Securities
    11/13/2025$280.00Sector Outperform
    Scotiabank
    11/4/2025$237.00Buy → Hold
    DZ Bank
    10/14/2025Buy → Hold
    Erste Group
    10/1/2025Buy → Hold
    HSBC Securities
    9/17/2025$270.00Hold → Buy
    Berenberg
    More analyst ratings

    $ABBV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Quaggin Susan E

    4 - AbbVie Inc. (0001551152) (Issuer)

    1/5/26 5:00:15 PM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Alpern Robert J

    4 - AbbVie Inc. (0001551152) (Issuer)

    1/5/26 5:00:18 PM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Rapp Edward J

    4 - AbbVie Inc. (0001551152) (Issuer)

    1/5/26 5:00:10 PM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABBV
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    AbbVie Reports Full-Year and Fourth-Quarter 2025 Financial Results

    Reports Full-Year Diluted EPS of $2.36 on a GAAP Basis, a Decrease of 1.3 Percent; Adjusted Diluted EPS of $10.00, a Decrease of 1.2 Percent; These Results Include an Unfavorable Impact of $2.76 Per Share Related to 2025 Acquired IPR&D and Milestones Expense  Delivers Full-Year Net Revenues of $61.160 Billion, an Increase of 8.6 Percent on a Reported Basis and 8.5 Percent on an Operational Basis  Full-Year Global Net Revenues from the Immunology Portfolio Were $30.406 Billion, an Increase of 14.0 Percent on a Reported Basis, or 13.9 Percent on an Operational Basis; Global Skyrizi Net Revenues Were $17.562 Billion; Global Rinvoq Net Revenues Were $8.304 Billion; Global Humira Net Revenues Wer

    2/4/26 7:48:00 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Allergan Aesthetics Continues Its Mission of Empowering Women Through the Faces of Natrelle® Testimonial Program

    The nationwide program invites eligible Natrelle® breast augmentation and reconstruction patients to share their personal experiences.Natrelle® champions women's voices to provide support at every step of their breast aesthetics journey.IRVINE, Calif., Feb. 3, 2026 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE:ABBV), announced the launch of the Faces of Natrelle® Testimonial Program, a nationwide initiative inviting women to share their real stories and experiences with Natrelle® breast implants to help educate, empower, and support others considering breast surgery.

    2/3/26 8:50:00 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AbbVie Submits Regulatory Applications to FDA and EMA for Upadacitinib (RINVOQ®) in Adults and Adolescents With Vitiligo

    Submissions are supported by data from the Phase 3 Viti-Up clinical studies demonstrating upadacitinib achieved the co-primary endpoints of at least a 50% improvement in total body re-pigmentation (T-VASI 50) and at least a 75% improvement in facial re-pigmentation (F-VASI 75) from baseline at week 48.1If approved, upadacitinib will be the first systemic medication available for patients with vitiligo, addressing important treatment needs for those living with the chronic, unpredictable autoimmune disease. NORTH CHICAGO, Ill., Feb. 3, 2026 /PRNewswire/ -- AbbVie (NYSE:ABBV) today announced that it has submitted applications for a new indication to the U.S. Food and Drug Administration (FDA)

    2/3/26 8:00:00 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABBV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    $ABBV
    SEC Filings

    View All

    AbbVie downgraded by Wolfe Research

    Wolfe Research downgraded AbbVie from Outperform to Peer Perform

    1/8/26 8:35:39 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    UBS resumed coverage on AbbVie with a new price target

    UBS resumed coverage of AbbVie with a rating of Neutral and set a new price target of $240.00

    1/7/26 9:08:42 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AbbVie upgraded by HSBC Securities with a new price target

    HSBC Securities upgraded AbbVie from Hold to Buy and set a new price target of $265.00

    12/10/25 8:10:03 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AbbVie Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - AbbVie Inc. (0001551152) (Filer)

    2/4/26 7:54:33 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AbbVie Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - AbbVie Inc. (0001551152) (Filer)

    1/7/26 4:08:59 PM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by AbbVie Inc.

    10-Q - AbbVie Inc. (0001551152) (Filer)

    11/4/25 2:05:49 PM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABBV
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for VYALEV issued to ABBVIE INC

    Submission status for ABBVIE INC's drug VYALEV (ORIG-1) with active ingredient FOSCARBIDOPA AND FOSLEVODOPA has changed to 'Approval' on 10/16/2024. Application Category: NDA, Application Number: 216962, Application Classification: Type 3 - New Dosage Form and Type 4 - New Combination

    10/18/24 4:38:13 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for VYALEV issued to ABBVIE INC

    Submission status for ABBVIE INC's drug VYALEV (ORIG-1) with active ingredient FOSCARBIDOPA AND FOSLEVODOPA has changed to 'Approval' on 10/16/2024. Application Category: NDA, Application Number: 216962, Application Classification: Type 3 - New Dosage Form

    10/17/24 1:29:31 PM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for SKYRIZI issued to ABBVIE INC

    Submission status for ABBVIE INC's drug SKYRIZI (SUPPL-7) with active ingredient RISANKIZUMAB-RZAA has changed to 'Approval' on 06/18/2024. Application Category: BLA, Application Number: 761262, Application Classification:

    6/21/24 4:38:17 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABBV
    Leadership Updates

    Live Leadership Updates

    View All

    AbbVie Appoints CEO Robert A. Michael as Chairman of the Board of Directors

    Richard A. Gonzalez to retire from the board of directors effective July 1, 2025NORTH CHICAGO, Ill., Feb. 14, 2025 /PRNewswire/ -- AbbVie (NYSE:ABBV) today announced that its board of directors has unanimously elected chief executive officer (CEO) Robert A. Michael to assume the additional position of chairman, effective July 1, 2025. He will succeed Richard A. Gonzalez, who formerly served as AbbVie's CEO and has been chairman since the Company's formation in 2013. "I want to extend my heartfelt gratitude to Rick for his remarkable leadership and dedicated service," said Roxanne S. Austin, lead independent director. "The board and I have complete confidence in Rob, and we are fortunate to

    2/14/25 7:40:00 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PureTech Founded Entity Seaport Therapeutics Names Lauren White as Chief Financial Officer

    Former ImmunoGen CFO will join Seaport to steer capital financing strategy, accounting, FP&A and investor relations PureTech Health plc (NASDAQ:PRTC, LSE: PRTC)) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company, noted that its Founded Entity, Seaport Therapeutics, ("Seaport") a biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced the appointment of Lauren White as Chief Financial Officer. An accomplished biotech financial executive, Ms. White most recently served as the Chief Financial Officer at ImmunoGen (NASDAQ:IMGN) prior to its acquisition by AbbVie (NYSE:ABBV) for $10.1 billion in 2024. T

    11/5/24 7:05:00 AM ET
    $ABBV
    $CCCC
    $IMGN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Seaport Therapeutics Names Lauren White as Chief Financial Officer

    Former ImmunoGen CFO will join Seaport to steer capital financing strategy, accounting, FP&A and investor relations Seaport Therapeutics ("Seaport or the "Company"), a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced the appointment of Lauren White as Chief Financial Officer. An accomplished biotech financial executive, Ms. White most recently served as the Chief Financial Officer at ImmunoGen (NASDAQ:IMGN) prior to its acquisition by AbbVie (NYSE:ABBV) for $10.1 billion in 2024. "I am so pleased to welcome Lauren as our CFO as we progress our clinical-stage pipeline of therapeutics for the treatme

    11/5/24 7:00:00 AM ET
    $ABBV
    $CCCC
    $IMGN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    $ABBV
    Financials

    Live finance-specific insights

    View All

    AbbVie Reports Full-Year and Fourth-Quarter 2025 Financial Results

    Reports Full-Year Diluted EPS of $2.36 on a GAAP Basis, a Decrease of 1.3 Percent; Adjusted Diluted EPS of $10.00, a Decrease of 1.2 Percent; These Results Include an Unfavorable Impact of $2.76 Per Share Related to 2025 Acquired IPR&D and Milestones Expense  Delivers Full-Year Net Revenues of $61.160 Billion, an Increase of 8.6 Percent on a Reported Basis and 8.5 Percent on an Operational Basis  Full-Year Global Net Revenues from the Immunology Portfolio Were $30.406 Billion, an Increase of 14.0 Percent on a Reported Basis, or 13.9 Percent on an Operational Basis; Global Skyrizi Net Revenues Were $17.562 Billion; Global Rinvoq Net Revenues Were $8.304 Billion; Global Humira Net Revenues Wer

    2/4/26 7:48:00 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AbbVie to Host Full-Year and Fourth-Quarter 2025 Earnings Conference Call

    NORTH CHICAGO, Ill., Jan. 7, 2026 /PRNewswire/ -- AbbVie (NYSE:ABBV) will announce its full-year and fourth-quarter 2025 financial results on Wednesday, February 4, 2026, before the market opens. AbbVie will host a live webcast of the earnings conference call at 8 a.m. Central time. It will be accessible through AbbVie's Investor Relations website at investors.abbvie.com. An archived edition of the session will be available later that day. About AbbVie AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key t

    1/7/26 8:00:00 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AbbVie Reports Third-Quarter 2025 Financial Results

    Reports Third-Quarter Diluted EPS of $0.10 on a GAAP Basis, a Decrease of 88.6 Percent; Adjusted Diluted EPS of $1.86, a Decrease of 38.0 Percent; These Results Include an Unfavorable Impact of $1.50 Per Share Related to Acquired IPR&D and Milestones Expense  Delivers Third-Quarter Net Revenues of $15.776 Billion, an Increase of 9.1 Percent on a Reported Basis or 8.4 Percent on an Operational Basis Third-Quarter Global Net Revenues from the Immunology Portfolio Were $7.885 Billion, an Increase of 11.9 Percent on a Reported Basis, or 11.2 Percent on an Operational Basis; Global Skyrizi Net Revenues Were $4.708 Billion; Global Rinvoq Net Revenues Were $2.184 Billion; Global Humira Net Revenues

    10/31/25 7:49:00 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABBV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by AbbVie Inc. (Amendment)

    SC 13G/A - AbbVie Inc. (0001551152) (Subject)

    2/13/24 4:55:55 PM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by AbbVie Inc. (Amendment)

    SC 13G/A - AbbVie Inc. (0001551152) (Subject)

    1/25/24 4:59:27 PM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by AbbVie Inc. (Amendment)

    SC 13G/A - AbbVie Inc. (0001551152) (Subject)

    2/9/23 10:54:46 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care